Centivax completed $45 million Series A Round funding
Sector:
Life Science
Biotech
07/08/2025
S. San Francisco, CA USA
Centivax
completed $45 million Series A Round funding. Investors include
Future Ventures (lead), NfX, BOLD Capital Partners, Kendall Capital Partners, Amplify Partners, Base4 Capital.
Centivax is led by CEO and founder Dr. Jacob Glanville, former founder and CEO of Distributed Bio, whose clients included Pfizer, Boehringer, Gilead, Teva, and 60 other biotechs and pharmaceutical companies and was acquired by Charles River Laboratories in 2020; Chief Medical Officer Dr. Jerald Sadoff, who previously led vaccine development at Johnson & Johnson, Merck, WRAIR, and AERAS, resulting in 14 vaccines receiving regulatory approval, including Gardasil®, Zostavax™, ProQuad®, Rotateq®, and the Janssen Jcovden COVID-19 vaccine; Chief Scientific Officer and co-founder Dr. Sawsan Youssef, who successfully exited Distributed Bio with Glanville in 2020, and whose work at Pfizer led to the clinical-stage drug sasanlimab; and co-founder and Chief Business Officer Stephanie Wisner, MBA, formerly of ARCH Venture Partners and author of Building Backwards to Biotech. The leadership team also includes Chief Innovation Officer Dr. Gusti Zeiner, Chief Operations Officer and co-founder David Tsao, and Chief Technology Officer and co-founder Dr. Nicholas Bayless.
About
Centivax is a universal immunity company, deploying a proprietary computational immune-engineering platform to create vaccines and therapies that deliver universal protection against entire classes of diverse targets. The lead clinical candidate for influenza—featured in The New Yorker, the Netflix docuseries Pandemic: How to Prevent an Outbreak, and other outlets—addresses a greater than $7 billion global flu market, with follow-on programs spanning a growing pipeline for RSV/hMPV, herpesviruses, HIV, malaria, oncology, and a universal antivenom. This growing portfolio underscores the technology's broad potential not only to protect against a wide array of infectious diseases–including viral, bacterial, protozoan, fungal, parasitic and man-made bioterror threats–but also to improve healthspan by reducing the long-term complications these pathogens can trigger, such as cancer, autoimmune conditions, cardiovascular and neurodegenerative disease.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
